Citius Oncology, Inc. (CTOR) Current Ratio
- Current ratio · latest quarter: Value 0.73×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 0.73× | Current assets / current liabilities. $42.71M ÷ $58.79M ≈ 0.73× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 42.71M USD | Assets, Current |
| Current obligations | 58.79M USD | Liabilities, Current |
| Cash and equivalents | 16.56M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | 686.24K USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | 22.63M USD | Inventory, Net |
| Payables | 7.32M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $42.71M | $58.79M | $16.56M | (m) | $686.24K | $22.63M | $7.32M | (m) | 0.73× |
| 2026-03-31 | $29.42M | $58.81M | $2.63M | (m) | $1.08M | $22.66M | $8.88M | (m) | 0.50× |
| 2025-12-31 | $37.15M | $44.71M | $7.30M | (m) | $4.05M | $22.64M | $10.45M | (m) | 0.83× |
| 2025-09-30 | $27.54M | $49.49M | $3.92M | (m) | (m) | $22.29M | $13.23M | (m) | 0.56× |
| 2025-06-30 | $18.31M | $52.99M | $112.00 | (m) | (m) | $17.21M | $8.67M | (m) | 0.35× |
| 2025-03-31 | $18.04M | $49.74M | $112.00 | (m) | (m) | $15.34M | $7.68M | (m) | 0.36× |
| 2024-12-31 | $17.08M | $43.40M | (m) | (m) | (m) | $14.38M | $5.87M | (m) | 0.39× |
| 2024-09-30 | $10.97M | $32.70M | (m) | (m) | (m) | $8.27M | $3.71M | (m) | 0.34× |
| 2024-06-30 | $40.99K | $3.08M | (m) | (m) | (m) | (m) | (m) | (m) | 0.01× |
| 2024-03-31 | $94.39K | $2.82M | (m) | (m) | (m) | (m) | (m) | (m) | 0.03× |
| 2023-12-31 | $58.20K | $2.05M | (m) | (m) | (m) | (m) | (m) | (m) | 0.03× |
| 2023-09-30 | $7.73M | $21.05M | (m) | (m) | (m) | (m) | $1.29M | (m) | 0.37× |
| 2023-06-30 | $461.91K | $463.88K | (m) | (m) | (m) | (m) | (m) | (m) | 1.00× |
| 2023-03-31 | $245.37K | $47.78K | (m) | (m) | (m) | (m) | (m) | (m) | 5.14× |
| 2022-12-31 | $377.34K | $31.84K | (m) | (m) | (m) | (m) | (m) | (m) | 11.85× |
| 2021-12-31 | $126.42K | $136.53K | (m) | (m) | (m) | (m) | (m) | (m) | 0.93× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |